TABLE 1.
Clinical trials with bevacizumab in ovarian cancer.
| Name of the study | Year of the study | Phase of the study | Research group | Dose of bevacizumab | Results |
|---|---|---|---|---|---|
| GOG-218 (Burger et al., 2011) | 2011 | III | 1873, (control therapy n = 625, bevacizumab-initiation therapy n = 625, bevacizumab-throughout therapy n = 623) | Bevacizumab-initiation: chemotherapy + bevacizumab (15 mg/kg), cycles 2–6, placebo, cycles 7–22; bevacizumab-throughout: chemotherapy + bevacizumab, cycles: 2–22 | Control group, bevacizumab-initiation group, bevacizumab-throughout group: PFS 10.3, 11.2, 14.1 months; OS 39.3, 38.7, 39.7 months, respectively |
| ICON-7 (Oza et al., 2015) | 2015 | III | 1,528, (standard chemotherapy n = 764, chemotherapy plus bevacizumab n = 764) | 7.5 mg/kg every 3 weeks | Standard chemotherapy group, chemotherapy plus bevacizumab group: PFS 34.5, 36.3 months; OS 44.6, 45.4 months, respectively |
| PAOLA-1 (Ray-Coquard et al., 2023) | 2023 | III | 806, (olaparib plus bevacizumab n = 537, placebo plus bevacizumab n = 269) | 15 mg/kg every 3 weeks for 15 months | Olaparib plus bevacizumab, placebo plus bevacizumab: OS 56.5, 51.6 months, respectively |
| AGO-OVAR 17 BOOD/GINECO OV118/ENGOT Ov15 (Pfisterer et al., 2023) | 2023 | III | 927, (standard chemotherapy plus bevacizumab for 15 months n = 464, standard chemotherapy plus bevacizumab for 30 months n = 463) | 15 mg/kg once every 3 weeks for 15 or 30 months | Standard chemotherapy plus bevacizumab for 15 months, standard chemotherapy plus bevacizumab for 30 months: PFS 24.2, 26.0 months; OS 60.4, 60.8 months, respectively |
| Gilbert et al. (Gilbert et al., 2023) | 2023 | Ib/II | 94, (combination treatment with mirvetuximab soravtansine and bevacizumab n = 94) | 15 mg/kg | PFS: 8.2 months, DOR: 9.7 months |
PFS, progression-free survival; OS, overall survival; DOR, duration of response.